Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott received FDA clearance for the FreeStyle Libre 2 iOS app, enhancing diabetes management with real-time glucose monitoring accessible via compatible iPhones. This innovation allows users and caregivers to track glucose levels without a reader, making diabetes management easier and more affordable. The app supports users aged 4 and older and integrates with the LibreLinkUp app for remote monitoring. With a 14-day wear time, the FreeStyle Libre 2 sensor is the longest-lasting on the market. Abbott's system is widely accessible, with reimbursement in 38 countries, including the U.S.
A study by Ohio State University and Abbott reveals that half of adults with diabetes fail to meet daily protein intake recommendations, which correlates with lower diet quality and increased physical limitations. The research analyzed over 23,000 adults, finding that inadequate protein intake leads to poorer nutrient density and higher carbohydrate consumption. Abbott's Glucerna 30g protein shake aims to address this gap, providing a nutritional option for diabetes management. The study underscores the significance of balancing nutrient intake to support strength and mobility in diabetes patients.
Abbott (NYSE: ABT) reported strong financial results for Q2 2021, with sales of $10.2 billion, a 39.5% increase year-over-year. Diluted EPS grew to $0.66 GAAP and $1.17 adjusted, reflecting a 105.3% rise. Key segments driving growth included Diagnostics, which surged 62.8% due to $1.3 billion in COVID-19 testing, and Medical Devices, which rose 51.3%. Abbott projects full-year diluted EPS between $2.75 and $2.95, with adjusted EPS of $4.30 to $4.50. The company declared its 390th consecutive quarterly dividend of $0.45, showcasing its commitment to shareholder returns.
Abbott (NYSE: ABT) announced FDA approval for its XIENCE stents, allowing a one-month DAPT (Dual Antiplatelet Therapy) duration for high bleeding risk (HBR) patients. This makes it the shortest DAPT indication globally. Additionally, the next-generation XIENCE Skypoint stent received FDA and CE Mark approval, designed for easier placement and effective treatment of larger vessels. The approvals are backed by extensive clinical data, affirming the safety of early DAPT discontinuation with XIENCE stents, which can improve patient outcomes while minimizing bleeding risks.
Abbott announced at the ADA 81st Scientific Sessions significant findings regarding its FreeStyle Libre continuous glucose monitoring (CGM) system, demonstrating its potential to enhance health equity for Americans with diabetes. The data indicated notable improvements in health outcomes, including reduced HbA1C levels and fewer acute complications, particularly among diverse and underserved populations. Moreover, increasing FreeStyle Libre usage could potentially save Medicaid $23 million annually by minimizing health complications.
Abbott (NYSE: ABT) will release its second-quarter 2021 financial results on July 22, 2021, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), which can be accessed via Abbott's Investor Relations website. Abbott is a leader in healthcare, providing technologies that improve health outcomes across various segments, including diagnostics and medical devices, with operations in over 160 countries.
Abbott's recent Harris Poll survey reveals that 93% of U.S. adults exercising intensely recognize hydration's importance during workouts. However, 46% wrongly believe energy drinks help rehydrate after exercise, contradicting scientific advice. Dehydration occurs when fluid loss exceeds intake, affecting performance and recovery. Abbott promotes its Pedialyte Sport as an optimal rehydration solution with three times the electrolytes and less sugar than leading sports drinks. The survey included 2,047 adults, with 799 participating in intense exercise at least thrice weekly.
Abbott's internship program enables high school students to earn college credit for STEM internships, a first endorsed by the American Council on Education. Over nearly a decade, the program has supported diverse students, with 60% coming from underrepresented backgrounds. This initiative is part of Abbott's 2030 Sustainability Plan, aiming to provide STEM opportunities to 100,000 young people, including women and underrepresented groups. The program aims to inspire more students to pursue STEM careers and has already fostered a talent pipeline for Abbott's workforce.
Abbott's board of directors declared a quarterly dividend of 45 cents per share, marking the 390th consecutive quarterly dividend since 1924. This dividend is payable on August 16, 2021, to shareholders on record as of the close of business on July 15, 2021. Abbott has a strong track record, having increased its dividend payout for 49 consecutive years and is recognized as a member of the S&P 500 Dividend Aristocrats Index.
Abbott announced its readiness to meet the increasing demand for mechanical circulatory support (MCS) devices, particularly after Medtronic's discontinuation of the HeartWare™ ventricular assist device. Abbott's HeartMate 3 heart pump is now available for patients with advanced heart failure, including those awaiting transplants. The device boasts a mortality benefit with 87% survival at one year. Abbott is enhancing support and education for physicians adopting HeartMate 3, which has assisted nearly 18,000 patients globally and can significantly improve quality of life.